Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Loupakis, Fotios ^a   Ruzzo, Annamaria ^b   Salvatore, Lisa ^a   Cremolini, Chiara ^a   Masi, Gianluca ^a   Frumento, Paolo ^c   Schirripa, Marta ^a   Catalano, Vincenzo ^d   Galluccio, Nadia ^b   Canestrari, Emanuele ^b   Vincenzi, Bruno ^e   Santini, Daniele ^e   Bencardino, Katia ^f   Ricci, Vincenzo ^f   Manzoni, Mariangela ^g   Danova, Marco ^g   Tonini, Giuseppe ^e   Magnani, Mauro ^b   Falcone, Alfredo ^a   Graziano, Francesco ^d  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c SCUOLA SUPERIORE SANT ANNA   (Italy)

^d SAN SALVATORE HOSPITAL   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

5' UNTRANSLATED REGION; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN THROMBOSIS; ADENOCARCINOMA; ALLELE; COLORECTAL TUMOR; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ALLELES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79958261031     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-247     Document Type: Article

References (28)

1. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br J Cancer 2009, 100:1704-1719. 10.1038/sj.bjc.6605061, 2695695, 19436303.
2. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096. 10.1200/JCO.2009.21.9170, 19188670.
3. Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Erbitux. , http://www.emea.europa.eu/pdfs/human/opinion/Erbitux_28040208en.pdf
4. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820.
5. Avastin: Highlights of prescribing information. , http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf
6. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847. 10.1093/annonc/mdp233, 19406901.
7. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300:2277-2285. 10.1001/jama.2008.656, 19017914.
8. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 14:22-28.
9. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97:981-989. 10.1093/jnci/dji174, 15998951.
10. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
11. Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 2007, 8:49-66. 10.2217/14622416.8.1.49, 17187509.
12. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000, 37:443-448. 10.1159/000054076, 11146397.
13. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000, 12:1232-1235. 10.1006/cyto.2000.0692, 10930302.
14. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 2006, 8:R22. 10.1186/bcr1400, 1557725, 16613616.
15. Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 2006, 96:209-215. 10.1007/s10549-005-9003-0, 16505966.
16. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678. 10.1200/JCO.2008.16.1612, 2653128, 18824714.
17. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008, 14:7554-7563. 10.1158/1078-0432.CCR-08-0351, 2586993, 19010874.
18. Lambrechts D, Delmar P, Buysschaert I, Claes B, Yesilyurt B, Verslype C, Foernzler D, Carmeliet P, Scherer S, Van Cutsem E. VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer. Eur J Cancer 2009, 7. (suppl; abstr 16LBA).
19. Koutras A, Antonacopoulou A, Fostira F, Briasoulis C, Sgouros I, Koumarianou A, Xiros N, Christodoulou C, Fountzilas G, Kalofonos H. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. J Clin Oncol 2010, 28(15s). (suppl; abstr 3587).
20. Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002, 13:308-317. 10.1093/annonc/mdf034, 11886010.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
22. NCI-CTCAE criteria. , http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215. 10.1093/nar/16.3.1215, 334765, 3344216.
24. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
25. Schneider B, Wang M, Sledge G, Gray R, Flockhart D, Miller K. In reply to: Race to Report: Are Vascular Endothelial Growth Factor Genetic Polymorphisms Associated With Outcome in Advanced Breast Cancer Patients Treated With Paclitaxel Plus Bevacizumab?. J Clin Oncol 2009, 27:1342-1343.
26. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
27. Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin-and/or irinotecan-based chemotherapy. Br J Cancer 2009, 100:881-887. 10.1038/sj.bjc.6604955, 2661784, 19259089.
28. Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 2005, 16:1305-1310. 10.1093/annonc/mdi244, 15857840.